Physician profile
Jonathan Wilson
NPI 1881738532
$7,524.08
in general payments reported to CMS, 2019-2025
22 companies · $3,560 in 2025
The $3,560 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $626 · 2021: $451 · 2022: $1,004 · 2023: $574 · 2024: $679 · 2025: $3,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,671 · Entertainment: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,671.35 |
| Entertainment | $140.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $3,020.16 | 2025 | M22 |
| Alcon Vision LLC | $1,310.67 | 2019-2025 | Total30, Precision7 |
| Bausch & Lomb Americas INC. | $501.80 | 2022-2025 | Infuse, Vyzulta, Scoutpro Osmolarity System |
| Mallinckrodt Hospital Products INC. | $458.24 | 2021-2024 | Acthar |
| Coopervision INC. | $299.72 | 2019-2024 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Optos, INC. | $256.67 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $246.54 | 2019-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $242.90 | 2019-2023 | |
| Allergan, INC. | $238.55 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $226.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $221.34 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $117.49 | 2025 | |
| Kala Pharmaceuticals, INC. | $107.70 | 2020-2022 | |
| Harrow Eye, LLC | $65.44 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $56.59 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $28.83 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $25.96 | 2024 | Xdemvy |
| Thea Pharma INC. | $23.57 | 2025 | Iyuzeh |
| Shire North American Group INC | $22.06 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.92 | 2021 | |
| Horizon Therapeutics Plc | $18.53 | 2023 | |
| Sight Sciences, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.